Page 18

Highlights

Photo Courtesy of Duke Today

DUKE UNIVERSIT Y SCHOOL OF MEDICINE

Senate Confirms Califf as Next FDA Head FEBRUA RY 2 4 , 2 016

Paul Modrich, PhD, in his laboratory at Duke University School of Medicine.

Paul Modrich Receives Nobel Prize in Chemistry DECEMBER 10, 2 015

|

DUK E UNI V ER SIT Y MED SCHOOL BLOG

On Wednesday, October 7, 2015, the Royal Swedish Academy of Sciences announced that Paul Modrich, PhD, a Howard Hughes Medical Institute (HHMI) investigator at Duke University; Tomas Lindahl of the Francis Crick Institute and Clare Hall Laboratory in the UK; and Aziz Sancar of University of North Carolina, Chapel Hill, are the recipients of the 2015 Nobel Prize in Chemistry for mechanistic studies of DNA repair. Dr. Modrich, a professor in the Department of Biochemistry, joined Duke in 1976. He is a James B. Duke Professor of Biochemistry and a member of the Duke Cancer Institute. The 2015 Nobel Prize Award Ceremony took place at Stockholm Concert Hall on Thursday, December 10, 2015. n

Duke Medicine Becomes Duke Health J A NUA RY 15, 2 016

|

DUK E HE A LTH NE W S & COMMUNIC ATIONS

On January 13, Duke Medicine began a transition to a new name: Duke Health. As with Duke Medicine, Duke Health is not a legal entity but will serve as an overarching brand name that conceptually refers to all assets and entities within the Duke University Health System, the Duke University School of Medicine, and the Duke University School of Nursing. The ultimate goals will continue to be improving the health of individuals and communities. This decision was confirmed as a result of widespread discussions involving faculty, staff, trainees, alumni, board members and others in which a renewed focus on health clearly emerged as a 16

|

DUKE ANESTHESIOLOGY

|

DUK E UNI V ER SIT Y MED SCHOOL BLOG

Robert Califf, MD, was sworn in as the next commissioner of the U.S. Food and Drug Administration (FDA), previously held by Margaret Hamburg. Prior to joining the FDA, Dr. Califf, a professor of medicine in the Duke University School of Medicine, served as vice chancellor of clinical and translational research at Duke, Robert Califf, MD executive director and founder of the Duke Clinical Research Institute (DCRI), and director of the Duke Translational Medicine Institute. During his time at Duke, Califf led many landmark clinical trials in cardiovascular disease. He is considered an international leader in the fields of health outcomes, quality of care and medical economics. He is one of the nation’s leaders in the growing field of translational research, which is key to adapting scientific advances into clinical care. “It’s a proud day for the DCRI and Duke,” said DCRI executive director, Dr. Eric Peterson. “Today marks another milestone in his storied career as a champion for improving patient care around the world. Dr. Califf has devoted his life to innovations in clinical research, and we look forward to his contribution to advancing and protecting our nation’s public health.” President Obama nominated Califf for the position in September of 2015. Califf has served as the FDA’s deputy commissioner for medical devices and tobacco since February 2015. n

core pursuit in a new strategic planning framework that will be introduced to the Duke Health community at the end of January. “Duke Health signals our intention to explore more comprehensive approaches to health that extend beyond medical care and into other determinants of population health improvement,” said A. Eugene Washington, M.D., Chancellor for Health Affairs, Duke University, and President and CEO, Duke University Health System. The transition to Duke Health likely will take most, if not all, of 2016. It will involve numerous changes of signage on Duke clinics and Duke Primary Care sites, changes to websites, and many other things. The logo, however, will be virtually identical to that of Duke Medicine except for the word “Health.” Like Duke Medicine, Duke Health will continue to derive its strength from the internationally renowned health care delivered by our world-class clinicians and care teams, the breakthroughs in knowledge driven by our distinguished community of researchers, and innovative training programs advanced by our exceptional educators around the world. “Importantly, the leading constant is the value we place on the dedicated, compassionate and high-performing individuals throughout our organization. They are the great strength of Duke Health,” Washington said. n

2016 BluePrint  
Read more
Read more
Similar to
Popular now
Just for you